Loading
Every dated change on the records linked to Locally advanced and metastatic basal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective response by independent central review in 26 of 84 patients (31 per cent, 95 per cent confidence interval 21 to 42) with five complete responses; grade 3 or 4 treatment-emergent adverse events in 48 per cent.
Surgical downstaging in 44 of 55 patients (80 per cent, 95 per cent confidence interval 67 to 90) with 27 complete responses, an objective response rate of 71 per cent, and recurrence in 16 of the 44 downstaged patients (36 per cent) by three years.
A milestone in how this cancer is treated.
Locally advanced BCC recurrent after surgery or radiation, or not candidates
Objective response at 200 mg: 43% in locally advanced and 15% in metastatic basal cell carcinoma (central review).
A milestone in how this cancer is treated.
Metastatic BCC or locally advanced BCC recurrent after surgery or not amenable to surgery/radiation
Objective response 43% in locally advanced and 30% in metastatic basal cell carcinoma (independent review).
A milestone in how this cancer is treated.